Women's Oncology Market Poised to Hit $110B by 2030 Amid Persistent Care Gaps

The women's oncology market is about to get a lot bigger—and a lot more complicated. A new analysis from PwC projects the global market for cancers affecting women will nearly double over the next four years, climbing from somewhere between $65 billion and $75 billion today to somewhere between $100 billion and $110 billion by 2030. That's a compound annual growth rate of 7 to 9 percent, driven largely by a shift toward targeted therapies that let doctors treat cancer with more precision and less collateral damage than the blunt instrument of traditional chemotherapy.

But the same report that forecasts this expansion also documents a stubborn reality: the money and the attention are not distributed evenly across women's cancers. In the United States alone, more than 400,000 women receive a diagnosis of breast or gynecologic cancer each year. Breast cancer has long dominated the landscape—both in terms of research dollars and public awareness. Ovarian cancer, by contrast, has been left in the shadows. The numbers tell the story plainly. In 2025, the National Institutes of Health spent roughly $70,000 per death on breast cancer research. For ovarian cancer, the figure was $43,000. That gap compounds over time, translating into more innovation for some cancers and stagnation for others.

The market opportunity itself is real and substantial. Pharmaceuticals account for nearly 70 percent of the projected market value, buoyed by strong reimbursement dynamics and the commercial appeal of scalable drug development. But the PwC analysis identifies critical gaps at every stage of the patient journey—from the moment a woman might be at risk, through diagnosis, treatment, and into survivorship. Early detection stands out as perhaps the most glaring unmet need, particularly for gynecologic cancers where symptoms often arrive late. Liquid biopsies, artificial intelligence-powered diagnostic tools, mobile screening programs, and at-home tests represent promising paths forward, but they remain unevenly distributed and underfunded.

The investment landscape has shifted somewhat in recent years. Between 2020 and 2025, private funding events in women's oncology totaled more than $6.5 billion across nearly 400 deals. Devices and diagnostics captured the largest share of deal volume, suggesting that investors see opportunity in the infrastructure of detection and monitoring. Yet this capital concentration also reveals where the gaps persist. Breast cancer's dominance in research and development did not happen by accident; it followed decades of sustained, substantial investment that created a virtuous cycle of innovation and commercial success. As money increasingly flows toward gynecologic cancers, the question becomes whether that same momentum can be replicated in areas where the unmet need remains acute.

The implications ripple across the healthcare system. Pharmaceutical companies now have tools—particularly artificial intelligence—to accelerate the discovery of biomarkers and speed up clinical development in gynecologic cancers, potentially compressing timelines that have historically stretched for years. Providers are beginning to build longitudinal care models that follow women from initial treatment through the long aftermath of survivorship, a shift driven partly by improving survival rates and partly by recognition that cancer does not end when chemotherapy does. Payers and employers, meanwhile, face pressure to expand coverage for early detection methods that have evidence behind them, a move that could shift the entire economics of women's oncology toward prevention and early intervention rather than late-stage treatment.

One more factor complicates the picture: the patients themselves are getting younger. As diagnoses trend downward in age, the healthcare system must reckon with the long-term consequences of treatment in women who may have decades of life ahead. Survivorship care, fertility preservation, and the management of treatment-related side effects become not peripheral concerns but central to the value proposition of any cancer program. The $110 billion market projected for 2030 will be built on the foundation of how well the system addresses these gaps—and whether the capital flowing into women's oncology reaches the cancers and the patients who need it most.